Clinical trials
Completed trials in Saudi Arabia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
1,078 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 3 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 12 |
| 2005 | 11 |
| 2006 | 11 |
| 2007 | 23 |
| 2008 | 27 |
| 2009 | 29 |
| 2010 | 30 |
| 2011 | 29 |
| 2012 | 27 |
| 2013 | 29 |
| 2014 | 37 |
| 2015 | 36 |
| 2016 | 42 |
| 2017 | 59 |
| 2018 | 80 |
| 2019 | 81 |
| 2020 | 104 |
| 2021 | 95 |
| 2022 | 82 |
| 2023 | 77 |
| 2024 | 69 |
| 2025 | 61 |
| 2026 | 17 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 1,078 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| King Saud University | 88 |
| King Abdulaziz University | 49 |
| Imam Abdulrahman Bin Faisal University | 45 |
| Cairo University | 42 |
| King Faisal Specialist Hospital & Research Center | 35 |
| Umm Al-Qura University | 35 |
| Novartis Pharmaceuticals | 31 |
| Qassim University | 27 |
| Novo Nordisk A/S | 26 |
| University of Jazan | 24 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 41 |
| Diabetes Mellitus | 29 |
| Pain | 29 |
| Cerebral Palsy | 28 |
| Obesity | 28 |
| COVID-19 | 25 |
| Breast Neoplasms | 24 |
| Osteoarthritis, Knee | 17 |
| Asthma | 16 |
| Stroke | 16 |
Trials
Showing 1 to 25 of 1,078. Each trial links to its page on Pharma Observatory.
978 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.